Novel montelukast sodium-loaded clear oral solution prepared with hydroxypropyl-β-cyclodextrin as a solubilizer and stabilizer: Enhanced stability and bioequivalence to commercial granules in rats

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 82, Issue 3, 2015, Pages 479-487

  Kim, Young Hun ^a,b   Kim, Dong Wuk ^a   Kwon, Min Seok ^a   Kwon, Taek Kwan ^b   Park, Jung Hee ^b   Jin, Sung Giu ^a   Kim, Kyung Soo ^a   Kim, Yong Il ^b   Park, Jae Hyun ^b   Kim, Jong Oh ^c   Yong, Chul Soon ^c   Woo, Jong Soo ^b   Choi, Han Gon ^a  

^a Hanyang University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

^c Yeungnam University   (South Korea)

Author keywords

Bioequivalence; Hydroxypropyl cyclodextrin; Montelukast sodium; Oral solution; Solubility; Stability

Indexed keywords

EID: 84944400414     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-015-0519-6     Document Type: Article

References (40)

1. Bennett, G., Craig, T.: Hereditary angioedema with a focus on the child. Allergy Asthma Proc. 36(1), 70-73 (2015)
2. Chong, J.K., Chauhan, B.F.: Addition of antileukotriene agents to inhaled corticosteroids in children with persistent asthma. Paediatr. Child Health 19(9), 473-474 (2014)
3. Gibson, P.G., Simpson, J.L., Ryan, N.M., Vertigan, A.E.: Mechanisms of cough. Curr. Opin. Allergy Clin. Immunol. 14(1), 55-61 (2014)
4. Strauch, E., Moske, O., Thoma, S., Storm Van's Gravesande, K., Ihorst, G., Brandis, M., Kuehr, J.: A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma. Pediatr. Res. 54(2), 198-203 (2003)
5. Aagaard, L., Hansen, E.H.: Adverse drug reactions associated with asthma medications in children: systematic review of clinical trials. Int. J. Clin. Pharm. 36(2), 243-252 (2014)
6. Paul, S.P., Bhatt, J.M.: Preschool wheeze is not asthma: a clinical dilemma. Indian J. Pediatr. 81(11), 1193-1195 (2014)
7. Patil-Gadhe, A., Pokharkar, V.: Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur. J. Pharm. Biopharm. 88(1), 160-168 (2014)
8. Okamoto, Y., Yokota, M., Kawazoe, S., Kubota, H., Nagaoka, H., Arakida, Y., Takeuchi, M.: A novel dual antagonist of thromboxane A2 and leukotriene D4 receptors: synthesis and structure-activity relationships of chloroquinolylvinyl derivatives. Chem. Pharm. Bull. 54(5), 603-610 (2006)
9. Okumu, A., DiMaso, M., Löbenberg, R.: Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm. Res. 25(12), 2778-2785 (2008)
10. Mahajan, H.S., Gundare, S.A.: Preparation, characterization and pulmonary pharmacokinetics of xyloglucan microspheres as dry powder inhalation. Carbohydr. Polym. 102, 529-536 (2014)
11. Muppavarapu, R., Guttikar, S., Rajappan, M., Kamarajan, K., Mullangi, R.: Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. Biomed. Chromatogr. 28(8), 1048-1056 (2014)
12. Al Omari, M.M., Zoubi, R.M., Hasan, E.I., Khader, T.Z., Badwan, A.A.: Effect of light and heat on the stability of montelukast in solution and in its solid state. J. Pharm. Biomed. Anal. 45(3), 465-471 (2007)
13. Rana, N.S., Rajesh, K.S., Patel, N.N., Patel, P.R., Limbachiya, U., Pasha, T.Y.: Development and validation of RP-HPLC method for the simultaneous estimation of montelukast sodium and ebastine in tablet dosage form. Indian J. Pharm. Sci. 75(5), 599-602 (2013)
14. Amirav, I., Luder, A.S., Kruger, N., Borovitch, Y., Babai, I., Miron, D., Zuker, M., Tal, G., Mandelberg, A.: A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics 122(6), e1249-e1255 (2008)
15. Medina, A.P., Olaya, F.J., Navas, M.P., Tilano, A.M., Muñoz, E.: Bioequivalence study of montelukast 5 mg chewable tablets. Biomedica 32(3), 399-407 (2012)
16. Stelmach, I., Jerzynska, J., Kuna, P.: A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clin. Exp. Allergy 32(2), 264-269 (2002)
17. Wang, K., Birring, S.S., Taylor, K., Fry, N.K., Hay, A.D., Moore, M., Jin, J., Perera, R., Farmer, A., Little, P., Harrison, T.G., Mant, D., Harnden, A.: Montelukast for postinfectious cough in adults: a double-blind randomised placebo-controlled trial. Lancet Respir. Med. 2(1), 35-43 (2014)
18. Ahmed, T.A., Ibrahim, H.M., Samy, A.M., Kaseem, A., Nutan, M.T., Hussain, M.D.: Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability. AAPS PharmSciTech. 15(3), 772-780 (2014)
19. Balani, S.K., Xu, X., Pratha, V., Koss, M.A., Amin, R.D., Dufresne, C., Miller, R.R., Arison, B.H., Doss, G.A., Chiba, M., Freeman, A., Holland, S.D., Schwartz, J.I., Lasseter, K.C., Gertz, B.J., Isenberg, J.I., Rogers, J.D., Lin, J.H., Baillie, T.A.: Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 25(11), 1282-1287 (1997)
20. Fey, C., Thyroff-Friesinger, U., Jones, S.: Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults. Clin. Transl. Allergy 4, 29 (2014)
21. Lim, H.T., Balakrishnan, P., Oh, D.H., Joe, K.H., Kim, Y.R., Hwang, D.H., Lee, Y.B., Yong, C.S., Choi, H.G.: Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: physicochemical characterization and pharmacokinetics in beagle dogs. Int. J. Pharm. 397, 225-230 (2010)
22. Kim, Y.I., Kim, K.S., Suh, K.H., Shanmugam, S., Woo, J.S., Yong, C.S., Choi, H.G.: New clopidogrel napadisilate salt and its solid dispersion with improved stability and bioequivalence to the commercial clopidogrel bisulphate salt in beagle dogs. Int. J. Pharm. 415, 129-139 (2011)
23. Kassem, M.G., Ezzeldin, E., Korashy, H.M., Mostafa, G.A.: High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 939, 73-79 (2013)
24. Cho, K.H., Choi, Y.K., Kang, J.H., Choi, H.G., Yong, C.S., Park, Y.J.: Development of a novel combination tablet containing trimebutine maleate and mosapride citrate for the treatment of functional dyspepsia. Int. J. Pharm. 400, 145-152 (2010)
25. Cho, K.H., Choi, H.G.: Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs. Drug Dev. Ind. Pharm. 39(6), 901-908 (2013)
26. Hughey, J.R., Keen, J.M., Miller, D.A., Kolter, K., Langley, N., McGinity, J.W.: The use of inorganic salts to improve the dissolution characteristics of tablets containing Soluplus®-based solid dispersions. Eur. J. Pharm. Sci. 48, 758-766 (2013)
27. Zhang, Y., Liu, Y., Luo, Y., Yao, Q., Zhong, Y., Tian, B., Tang, X.: Extruded soluplus/SIM as an oral delivery system: characterization, interactions, in vitro and in vivo evaluations. Drug Deliv. 30, 1-10 (2014)
28. Ramadhani, N., Shabir, M., McConville, C.: Preparation and characterisation of Kolliphor (®) P 188 and P 237 solid dispersion oral tablets containing the poorly water soluble drug disulfiram. Int. J. Pharm. 475, 514-522 (2014)
29. Sarode, A.L., Malekar, S.A., Cote, C., Worthen, D.R.: Hydroxypropyl cellulose stabilizes amorphous solid dispersions of the poorly water soluble drug felodipine. Carbohydr. Polym. 112, 512-519 (2014)
30. Tackenberg, M.W., Geisthövel, C., Marmann, A., Schuchmann, H.P., Kleinebudde, P., Thommes, M.: Mechanistic study of carvacrol processing and stabilization as glassy solid solution and microcapsule. Int. J. Pharm. 478(2), 597-605 (2014)
31. Ansari, M.T., Iqbal, I., Sunderland, V.B.: Dihydroartemisinin-cyclodextrin complexation: solubility and stability. Arch. Pharm. Res. 32(1), 155-165 (2009)
32. Orlu-Gul, M., Fisco, G., Parmar, D., Gill, H., Tuleu, C.: A new reconstitutable oral paediatric hydrocortisone solution containing hydroxypropyl-β-cyclodextrin. Drug Dev. Ind. Pharm. 39(7), 1028-1036 (2013)
33. Neves, J.S., Radke, A.L., Weller, P.F.: Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. J. Allergy Clin. Immunol. 125(2), 477-482 (2010)
34. Alvarez, C., Calero, J., Menéndez, J.C., Torrado, S., Torrado, J.J.: Effects of hydroxypropyl-beta-cyclodextrin on the chemical stability and the aqueous solubility of thalidomide enantiomers. Pharmazie 63(7), 511-513 (2008)
35. Battu, S.K., Repka, M.A., Maddineni, S., Chittiboyina, A.G., Avery, M.A., Majumdar, S.: Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. AAPS PharmSciTech. 11(3), 1466-1475 (2010)
36. Silva, G.H., Bottoli, C.B., Groppo, F.C., Volpato, M.C., Ranali, J., Ramacciato, J.C., Motta, R.H.: Methylparaben concentration in commercial Brazilian local anesthetics solutions. J. Appl. Oral Sci. 20(4), 444-448 (2012)
37. Turakka, L., Ojanen, T., Henell, U., Karjalainen, A.: Parabens as antimicrobial preservatives in creams. Pharmazie 43(10), 701-703 (1988)
38. Damian, F., Fabian, J., Friend, D.R., Kiser, P.F.: Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions. Int. J. Pharm. 396, 1-10 (2010)
39. Keowmaneechai, E., McClements, D.J.: Influence of EDTA and citrate on physicochemical properties of whey protein-stabilized oil-in-water emulsions containing CaCl2. J. Agric. Food Chem. 50, 7145-7153 (2002)
40. Zaid, A.N., Natour, S., Qaddomi, A., Abu Ghoush, A.: Formulation and in vitro and in vivo evaluation of film-coated montelukast sodium tablets using Opadry® yellow 20A82938 on an industrial scale. Drug Des. Devel. Ther. 7, 83-91 (2013)